Company Reports

Crispr Therapeutics’ second-quarter results are tracking our expectations, and its early-stage pipeline candidates are advancing in clinical trials. We continue to expect 2024 will be a pivotal year as Crispr rolls out commercialization efforts globally for its recently approved gene therapy, Casgevy, for the treatment of both sickle cell disease and transfusion-dependent beta thalassemia. We think Casgevy could hold strong pricing power and eventually become a blockbuster drug, generating over $1 billion annually in sales. We like that Crispr and Vertex are focused on opening approved treatment centers for Casgevy, and it has 35 centers active out of its plan to open around 75 across the globe. We maintain our positive long-term outlook and $119 fair value estimate. We view the stock as very undervalued, currently trading in 5-star territory. Crispr provides long-term investors who possess a high degree of risk tolerance with pure-play exposure to novel gene editing technology.

Crispr Therapeutics’ first-quarter results align with our expectations, and its early-stage pipeline candidates are advancing in clinical trials. We continue to expect 2024 will be a pivotal year as Crispr rolls out global commercialization efforts for its recently approved gene therapy, Casgevy, for the treatment of both sickle cell disease and transfusion-dependent beta thalassemia. We think Casgevy could hold strong pricing power and become a blockbuster drug, generating over $1 billion in revenue by 2026 for Crispr, pending a successful commercial launch.

Crispr Therapeutics is a clinical-stage gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced short palindromic repeats (Crispr)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. Crispr's emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

Crispr Therapeutics has achieved many recent milestones, most notably the approval of Casgevy for the treatment of patients with sickle cell disease or transfusion-dependent beta thalassemia. Clinical trials are advancing for its early-stage pipeline with candidates evaluating the treatment of Type 1 diabetes, liquid and solid tumors, and cardiovascular diseases. We maintain our positive long-term outlook and $119 fair value estimate. We view the stock as undervalued, trading in 4-star territory about 30% below our fair value estimate. Crispr provides long-term investors who possess a high degree of risk tolerance with pure-play exposure to novel gene editing technology.

Crispr Therapeutics has achieved many recent milestones, most notably the approval of Casgevy for the treatment of patients with either sickle cell disease or transfusion-dependent beta thalassemia. Additionally, clinical trials are advancing for its early-stage pipeline with candidates evaluating the treatment of Type 1 Diabetes, liquid and solid tumors, and cardiovascular diseases. We maintain our positive long-term outlook and fair value estimate of $119 per share. We view the stock as undervalued, currently trading in 4-star territory about 30% below our fair value estimate. Crispr provides long-term investors who possess a high degree of risk tolerance with pure-play exposure to novel gene editing technology.

CRISPR Therapeutics reported third-quarter results in line with our expectations, and its pipeline candidates are continuing to make progress. We maintain our positive outlook and fair value estimate of $119 per share. We view the stock as very undervalued, currently trading about 53% below our fair value estimate.

CRISPR Therapeutics reported second-quarter results in line with our expectations, and its pipeline candidates are continuing to make progress. Collaboration revenue totaled $70 million, which was largely attributable to a research milestone achieved in connection with CRISPR’s agreement with narrow-moat Vertex Pharmaceuticals. We maintain our positive outlook and fair value estimate of $119 per share. We view the stock as very undervalued, currently trading in 5-star territory about 55% below our fair value estimate.

CRISPR Therapeutics reported first-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our positive outlook and fair value estimate of $119 per share, and we view the stock as very undervalued. Collaboration revenue totaled $100 million in the quarter, which was largely attributable to an upfront payment from narrow-moat Vertex Pharmaceuticals. CRISPR ended the quarter in a healthy financial position with about $1.89 billion in cash, which will help fund its research and development expenses as it develops its pipeline candidates. Investors reacted favorably, sending the stock up 13%.

CRISPR Therapeutics is a clinical-stage gene editing company focused on the development of CRISPR/Cas9-based therapeutics. The company's proprietary platform specializes in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR’s emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.

CRISPR Therapeutics posted fourth-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our fair value estimate of $119 per share and view the stock as very undervalued, currently trading in 5-star territory. As a clinical-stage biotech company, CRISPR Therapeutics provides long-term investors who possess a high degree of risk tolerance with pure play exposure to novel gene editing technology to treat severe, genetic diseases.

CRISPR Therapeutics posted third-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our fair value estimate of $119 per share and view the stock as very undervalued, currently trading in 5-star territory. As a clinical-stage biotech company, CRISPR Therapeutics provides long-term investors with pure play exposure to novel gene editing technology to treat severe genetic diseases.

CRISPR Therapeutics reported second-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our fair value estimate of $119 per share and view the stock as undervalued, currently trading in 4-star territory. As a clinical-stage biotech company, CRISPR Therapeutics provides long-term investors with pure play exposure to novel gene editing technology to treat severe genetic diseases.

CRISPR Therapeutics reported first-quarter results in line with our forecasts. Its pipeline candidates are continuing to progress in development and are tracking our expectations. We maintain our $119 fair value estimate and view the shares as very undervalued, trading in 5-star territory. While the company does not yet have approved products, it provides long-term investors with pure-play exposure to novel gene editing technology to treat severe genetic diseases. It is developing several pipeline candidates spanning a diverse range of diseases with very high unmet needs, which will likely lead to pricing power if the drugs receive approval.

We assign CRISPR Therapeutics a fair value estimate of $119 per share and view the stock as undervalued, currently trading in 5-star territory. While the company does not yet have approved products, it provides long-term investors with pure play exposure to novel gene editing technology to treat severe, genetic diseases. We assign CRISPR a no-moat rating and positive trend. The company is developing several pipeline candidates spanning a diverse range of diseases with very high unmet needs, which will likely lead to pricing power if its drugs receive approval.

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. The company's proprietary platform specializes in Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9, which precisely cuts DNA to disrupt, delete, correct, and insert genes to treat genetically defined diseases. CRISPR’s emerging technology has led to a new class of therapies, which are well suited for targeting rare diseases or other disorders that are caused by genetic mutations.